Investoreight
Skip to main content

Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher

Benzinga
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate, VAX-31, showed promising results in a Phase 1/2 study, meeting or exceeding the immunogenicity criteria compared to Pfizer's Prevnar 20. Vaxcyte plans to initiate a Phase 3 study by mid-2025.
Continue Reading